leisure time -WSS

leisure time

author：explore 2025-09-03 03:24:23 - browse：52562

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What to expect as Trump is arraigned on his Jan 6. indictment

knowledge

hotspot

WSS

Breakthrough Alzheimer’s drugs are inaccessible in rural states

New safety details link Apellis eye drug to rare cases of blindness

Wildfire pollution widens asthma inequities on Long Island

Altering the blood type of lungs raises potential for universal organs for transplants

Bispecific antibodies are next new thing in cancer immunotherapy

Vertex non

leisure time

leisure time

leisure time

In Memoriam: Notable people who died in 2023

Reanimated hearts work just as well for transplants, study finds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Physician groups backed by private equity giant lobby on mergers

As demand for Covid shots wanes, Moderna seeks its next success

Wildfire pollution widens asthma inequities on Long Island

Guidelines to prevent youth baseball injuries need more muscle

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Medical records are filled with copy

A public health expert passes on football's full body collisions for youths

explore

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Reanimated hearts work just as well for transplants, study finds

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

knowledge

hotspot

focus

entertainment